Inhibiting IL-17 Improves Corneal Graft Survival
Author Information
Author(s): Chen XueDong, Zhao ShiYong, Tang XianLing, Ge HongYan, Liu Ping
Primary Institution: The First Affiliated Hospital of Harbin Medical University
Hypothesis
Does neutralizing IL-17 improve corneal allograft survival?
Conclusion
Neutralizing IL-17 bioactivity improves corneal graft survival and reduces rejection by decreasing inflammatory cell infiltration and pro-inflammatory cytokine secretion.
Supporting Evidence
- Neutralization of IL-17 with anti-IL-17 mAb prolonged allograft survival compared to control.
- Inflammatory immune cells in corneal stroma decreased in recipients treated with anti-IL-17 mAb.
- Pro-inflammatory cytokines like IFN-γ and IL-12p40 were significantly lower in treated groups.
Takeaway
This study shows that blocking a specific protein called IL-17 can help eye transplants last longer by reducing inflammation.
Methodology
Mice received corneal grafts and were treated with anti-IL-17 monoclonal antibody; graft survival and immune responses were assessed.
Limitations
The study primarily focuses on murine models, which may not fully translate to human conditions.
Participant Demographics
6- to 8-week-old female BALB/c and C57BL/6 mice.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website